key: cord-0716145-12b1slbp
authors: Rolfo, Christian; Cardona, Andrés F.; Ruiz-Patiño, Alejandro; Ariza, Santiago; Zatarain-Barron, Lucia; Pino, Luis E.; Viola, Lucia; Russo, Alessandro; Rojas, Leonardo; Ricaurte, Luisa; Arrieta, Oscar
title: Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients
date: 2020-07-09
journal: J Thorac Oncol
DOI: 10.1016/j.jtho.2020.06.019
sha: 00624a8e79f31fccd9cc02ac643e8481d78898af
doc_id: 716145
cord_uid: 12b1slbp

Abstract A new coronavirus, named SARS-CoV-2 by the World Health Organization (WHO), has rapidly spread around the world since its first reported case in late December of 2019 from Wuhan, China. As of mid-April 2020, this virus has affected more than 180 countries and territories, infecting more than 1,650,000 individuals and causing over 100.000 deaths. With ≈20 million new cases per year globally, cancer affects a significant portion of the population. Individuals affected by cancer are more susceptible to infections due to coexisting chronic diseases (cardiovascular, pulmonary and diabetes), overall poor health status, and systemic immunosuppressive states caused by both cancer and anticancer treatments. As a consequence, patients with malignancies, and especially with lung cancer who develop COVID19 experience more difficult outcomes. A recent multicenter study developed by the Hubei Anti-Cancer Association also documented that lung cancer patients had an increased risk of death, ICU requirement, risk of presenting severe or critical symptoms, and use of invasive mechanical ventilation. Here we present two representative cases of patients with lung cancer and COVID19 without respiratory compromise and with atypical and severe skin manifestations, findings that could be influenced by the chronic use of anti-PD1 antibodies.

On December 2019, the first four cases of an acute respiratory syndrome of unknown etiology were reported (SARS-CoV-2, COVID19) in Wuhan City, Hubei Province, China among people linked to a local seafood market. 1 Since then, SARS-CoV-2 has infected 1,484,811 people in 184 countries, generating 88,538 deaths (https://coronavirus.jhu.edu/map.html).

Epidemiological studies demonstrated that ~80% of patients had mild symptoms, 14% developed severe conditions and 5% fell critically ill. 2 Severity increases with age and the case fatality risk is higher among individuals with underlying chronic conditions, including cancer. 3 Cancer patients seem to have a higher risk of severe clinical events (mechanical ventilation requirement or ICU admission), compared to the general population.

The most frequent COVID19-related symptoms are fever (88.4%), cough (71.7%), fatigue (60.3%), dyspnea (44.2%), myalgias (35.7%) and chills (26%). 4 At the moment, the only existing record on dermatological disorders of COVID19 comes from Lombardy, Italy where 18/88 patients (20.4%) had some cutaneous involvement, 5 including erythematous rash, widespread urticaria and chickenpox-like vesicles. Trunk was the main involved region; itching was low or absent and usually lesions healed in few days. 5 Among NSCLC patients treated with anti-PD(L)-1 therapy cutaneous immune-related adverse events (irAEs) occur in ~40%, including morbilliform eruptions, pruritus, eczema, psoriasis, lichenoid dermatitis, bullous pemphigoid, sarcoidosis, vitiligo, dermatomyositis, and lupus like reactions. 6 Cutaneous irAEs primarily develop early, within 5 weeks of treatment initiation 7 albeit a recent metaanalysis 8 suggested that PD-1 inhibitor-associated cutaneous irAEs may have late onsets.

Here we present two cases of patients with NSCLC in chronic treatment with immunotherapy, an intervention that achieved a marked response and control of the disease. Recently, COVID19 infection was documented in both patients with minimal respiratory manifestations and extensive cutaneous involvement, in one of the cases with an extensive urticarial pattern, and in the other with a multiform erythema. In addition, treatment, skin biopsy findings, and the role of various serum markers are discussed.

In March 2017, a 62-year-old current smoker man was diagnosed with a T4N2M1b G3 stage IV squamous cell lung carcinoma with pleuro-pulmonary involvement. The NGS analysis evidenced a high TMB (14 Muts/Mb), p 16 INK4a R47f 4 , CUL3 splice site 265-2A>C , NFE2L2 G15R , RANBP2 R1126W , TERC amplification, and TP 53

. The PD-L1 tumor proportion score (TPS) was 40%. He started treatment with ipilimumab (1 mg/kg every 6 weeks) plus nivolumab (3 mg/kg every 2 weeks). After 6 months, he received immunotherapy combo with excellent tolerance except for a mild hypothyroidism requiring hormone-replacing therapy. After a partial response, IMRT (60 Gy) on the residual disease was performed. Subsequently, and upon finding a complete response in thorax (05/21/18), immunotherapy remained unchanged until January 2019. At that time, a brain MRI showed the presence of a solitary left frontal lesion with a cystic component. On 01/08/19, he underwent a complete neurosurgical resection (supplementary Figure 1 ) followed by stereotactic radiosurgery (SRS) and ipilimumab/nivolumab restart, maintaining a complete extracranial and brain response until March 2020. Two days after the last immunotherapy dose, the patient had contact with a flu-symptomatic person on 03/14/20. Forty-eight hours later he noticed the presence of fever in addition to fatigue, myalgia and chills (Figure 1) , followed by an urticarial papular lesions, with minimal erythema, located in the lower dorsal, lumbar and gluteal region. The lesions tended to be persistent and left a small purplish residue. In addition, it was found burning sensation of the compromised skin, severe joint pain and reactive polyarthritis. The only respiratory symptoms were nasal congestion with minimal pharyngeal exudation and mild dry cough. On 03/20/20 the presence of SARS-CoV-2 was confirmed and a skin biopsy was performed (supplementary Figure 2) . In order to assess prognosis and disease severity follow-up, taking into account absence of respiratory complications, serial ferritin, D-Dimer (DD), and IL6 in addition to ANAS and C4, to discard differential diagnoses, were evaluated 9 . Elevation of ferritin (940 ng/mL) and DD (2.600 ng/dL) was documented (Figure 2) 

In February 2019, a 58-year-old former smoker woman presented with terminal dysphagia and dry cough without dyspnea. Disease staging with a PET/CT scan and a brain MRI revealed a 36x34 mm mass located in the posterior basal segment of the right lower lobe, minimal pleural effusion, several ipsilateral pulmonary nodules and 3 small brain lesions at the right frontal lobe. Lung biopsy found a lung adenocarcinoma with Napsin expression and negativity for ALK, EGFR, ROS1, HER2, BRAF, and NTRK.

PD-L1 TPS 1-49%. On 03/18/19, she started treatment with carboplatin/pemetrexed/pembrolizumab with a partial response. At the end of induction phase, the two residual brain metastases were treated with SRS followed by pemetrexed/pembrolizumab maintenance, with mild fatigue and hypothyroidism requiring hormone-replacing therapy. On 03/17/20, she had direct contact with a subject with nonspecific flu symptoms who subsequently tested positive for SARS-CoV-2. On 03/20/20 she started with diarrhea without mucus or blood (4 stools/day) associated with fever and dry cough without dyspnea. Two days later, she noted the progressive appearance of several lesions with targetoid morphology and peripheral rim of erythema and a central zone of pallor was evident. Some manifest violaceous appearance with no true central clearing and they were late associated with painful oral ulcers. On 03/24/20 we confirmed the presence of SARS-CoV-2 by RT-PCR of nasopharyngeal swab. In parallel, a skin biopsy was taken. After finding progression of dermatological lesions and a normal chest X-ray, she started hydroxychloroquine (400 mg BID on day 1 200 mg BID for 10 days), hydroxyzine (25 mg BID) and desloratadine (5 mg/day). In addition, methylprednisolone 1 mg/kg/day, interventions that achieved rapid control of clinical findings. Also, a progressive reduction of ferritin and C reactive protein was found, without

showing a significant elevation of IL6 (Figure 4 ).

The two cases presented here had completed ≥1 year of treatment with an anti-PD1 antibody, intervention that achieved a major response. Neither of the two had previous skin manifestations, nor had they TNF-alpha, IL-6 and IFN-gamma, 11 all proteins clearly associated with the cytokine storm generated by COVID19 and were not associated with skin patterns of cutaneous toxicity of pemetrexed. 12 In contrast to the present case reports, patients with COVID19 who received immunotherapy had the highest death rates and chance of developing critical symptoms. 13 This discrepancy may be related to the low number of patients included in the present report; however, our cases did not present major respiratory symptoms, but rather atypical and severe dermatological findings. On the other hand, both patients had low levels of IL6, an important predictor of COVID19-associated fatality. 14 Due to the marked elevation of DD, one of the patients received low-molecular weight heparin, as recently recommended. 15 Marked DD elevation has been recently reported as one of the predictors of mortality in COVID19-infected patients. 16 On the other hand, skin manifestations such as urticarial have been reported in at least 19% of cases. It is worth mentioning that this report was largely based on a cohort of subjects who presented with classical symptoms or were suspected cases. 17 In the absence of respiratory symptoms and previous immunotherapy treatment one could assume that our patient's disease behavior is completely different.

Despite the controversy, and in the absence of sever pulmonary compromise with a unique cutaneous tropism of COVID19 in our patients, were offered steroids in both cases. Overall, no unique reason exists to expect that patients with COVID9 infection will benefit from corticosteroids, especially in front of ARDS, but in the presence of other manifestations alternative perspective may be useful.

At this moment, the possibility to modulate diverse inflammatory manifestations derived from COVID19 in cancer patients, many of them exposed to immunotherapy, remains open. Among others we will see the usefulness of convalescent serum, the use of low doses of cyclophosphamide, baricitinib, ruxolitinib and fedratinib, the last ones with potential in patients with dermatological manifestations. 

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19 and cancer: what we know so far

COVID-19 Signs and Symptoms Tracker. The Centre for Evidence-Based Medicine, The University of Oxford

Cutaneous Manifestations in COVID-19: A First Perspective

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies

Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

Hematological findings and complications of COVID-19

Review of cold-induced urticaria characteristics, diagnosis and management in a Western Canadian allergy practice

Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis

Revisiting cutaneous adverse reactions to pemetrexed

on behalf of the Hubei Anti-Cancer Association. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak

Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases